A breakthrough experimental drug has shown promising results in shrinking advanced prostate cancer tumours, offering new hope ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

A breakthrough in prostate cancer treatment has seen a drug shrink tumours in advanced disease ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...

Cancer metastasis -- the spread of cancer to other organs -- is the leading cause of death among cancer patients. Researchers have now uncovered a 'genetic signature' of 177 genes shared across ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...